Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome

Holley F. Allen, Cristina Mazzoni, Rubina A. Heptulla, Mary A. Murray, Nancy Miller, Laura Koenigs, Edward O. Reiter

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Objective: We evaluated the hypothesis that metformin would improve signs and symptoms of polycystic ovary syndrome (PCOS) in adolescents as compared to oral contraceptive pills (OCP) and have a favorable effect on obesity. Study Design: Thirty-five obese, post-menarchal, non-sexually active adolescents aged 12-21 years with PCOS and hyperinsulinism were randomly assigned to receive either OCP or metformin for 6 months. Results: There was a significant decrease in BMI in the two groups over time, from 40.1 to 38.6 in the OCP group, and 37.3 to 36.3 in the metformin group, p = 0.0026, but no significant difference in the degree of change between the two groups. Both groups had decreased free testosterone (OCP: 1.8 pg/ml to 0.96 pg/ml; metformin: 2.1 pg/ml to 1.6 pg/ml), p <0.0001, and improvements in insulin resistance as evidenced by increased glucose/insulin (G/I) ratio (p <0.005) and increased QUICK1 scores (p <0.0005). No significant differences in response to treatment were found between the metformin and OCP groups in outcome variables. Conclusion: Adolescents with PCOS treated with metformin or OCP experienced similar beneficial outcomes including reduction in androgen levels, weight loss, and increased insulin sensitivity. The choice of a treatment agent for long-term use will depend on safety profiles, therapeutic goals and patient adherence.

Original languageEnglish (US)
Pages (from-to)761-768
Number of pages8
JournalJournal of Pediatric Endocrinology and Metabolism
Volume18
Issue number8
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Polycystic Ovary Syndrome
Metformin
Oral Contraceptives
Randomized Controlled Trials
Insulin Resistance
Therapeutics
Hyperinsulinism
Patient Compliance
Androgens
Signs and Symptoms
Testosterone
Weight Loss
Obesity
Insulin
Safety
Glucose

Keywords

  • Adolescent
  • Metformin
  • Polycystic ovary syndrome

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. / Allen, Holley F.; Mazzoni, Cristina; Heptulla, Rubina A.; Murray, Mary A.; Miller, Nancy; Koenigs, Laura; Reiter, Edward O.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 18, No. 8, 08.2005, p. 761-768.

Research output: Contribution to journalArticle

Allen, Holley F. ; Mazzoni, Cristina ; Heptulla, Rubina A. ; Murray, Mary A. ; Miller, Nancy ; Koenigs, Laura ; Reiter, Edward O. / Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. In: Journal of Pediatric Endocrinology and Metabolism. 2005 ; Vol. 18, No. 8. pp. 761-768.
@article{9c92cfb4b4ce46ed880412c7fd53d5b4,
title = "Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome",
abstract = "Objective: We evaluated the hypothesis that metformin would improve signs and symptoms of polycystic ovary syndrome (PCOS) in adolescents as compared to oral contraceptive pills (OCP) and have a favorable effect on obesity. Study Design: Thirty-five obese, post-menarchal, non-sexually active adolescents aged 12-21 years with PCOS and hyperinsulinism were randomly assigned to receive either OCP or metformin for 6 months. Results: There was a significant decrease in BMI in the two groups over time, from 40.1 to 38.6 in the OCP group, and 37.3 to 36.3 in the metformin group, p = 0.0026, but no significant difference in the degree of change between the two groups. Both groups had decreased free testosterone (OCP: 1.8 pg/ml to 0.96 pg/ml; metformin: 2.1 pg/ml to 1.6 pg/ml), p <0.0001, and improvements in insulin resistance as evidenced by increased glucose/insulin (G/I) ratio (p <0.005) and increased QUICK1 scores (p <0.0005). No significant differences in response to treatment were found between the metformin and OCP groups in outcome variables. Conclusion: Adolescents with PCOS treated with metformin or OCP experienced similar beneficial outcomes including reduction in androgen levels, weight loss, and increased insulin sensitivity. The choice of a treatment agent for long-term use will depend on safety profiles, therapeutic goals and patient adherence.",
keywords = "Adolescent, Metformin, Polycystic ovary syndrome",
author = "Allen, {Holley F.} and Cristina Mazzoni and Heptulla, {Rubina A.} and Murray, {Mary A.} and Nancy Miller and Laura Koenigs and Reiter, {Edward O.}",
year = "2005",
month = "8",
language = "English (US)",
volume = "18",
pages = "761--768",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "8",

}

TY - JOUR

T1 - Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome

AU - Allen, Holley F.

AU - Mazzoni, Cristina

AU - Heptulla, Rubina A.

AU - Murray, Mary A.

AU - Miller, Nancy

AU - Koenigs, Laura

AU - Reiter, Edward O.

PY - 2005/8

Y1 - 2005/8

N2 - Objective: We evaluated the hypothesis that metformin would improve signs and symptoms of polycystic ovary syndrome (PCOS) in adolescents as compared to oral contraceptive pills (OCP) and have a favorable effect on obesity. Study Design: Thirty-five obese, post-menarchal, non-sexually active adolescents aged 12-21 years with PCOS and hyperinsulinism were randomly assigned to receive either OCP or metformin for 6 months. Results: There was a significant decrease in BMI in the two groups over time, from 40.1 to 38.6 in the OCP group, and 37.3 to 36.3 in the metformin group, p = 0.0026, but no significant difference in the degree of change between the two groups. Both groups had decreased free testosterone (OCP: 1.8 pg/ml to 0.96 pg/ml; metformin: 2.1 pg/ml to 1.6 pg/ml), p <0.0001, and improvements in insulin resistance as evidenced by increased glucose/insulin (G/I) ratio (p <0.005) and increased QUICK1 scores (p <0.0005). No significant differences in response to treatment were found between the metformin and OCP groups in outcome variables. Conclusion: Adolescents with PCOS treated with metformin or OCP experienced similar beneficial outcomes including reduction in androgen levels, weight loss, and increased insulin sensitivity. The choice of a treatment agent for long-term use will depend on safety profiles, therapeutic goals and patient adherence.

AB - Objective: We evaluated the hypothesis that metformin would improve signs and symptoms of polycystic ovary syndrome (PCOS) in adolescents as compared to oral contraceptive pills (OCP) and have a favorable effect on obesity. Study Design: Thirty-five obese, post-menarchal, non-sexually active adolescents aged 12-21 years with PCOS and hyperinsulinism were randomly assigned to receive either OCP or metformin for 6 months. Results: There was a significant decrease in BMI in the two groups over time, from 40.1 to 38.6 in the OCP group, and 37.3 to 36.3 in the metformin group, p = 0.0026, but no significant difference in the degree of change between the two groups. Both groups had decreased free testosterone (OCP: 1.8 pg/ml to 0.96 pg/ml; metformin: 2.1 pg/ml to 1.6 pg/ml), p <0.0001, and improvements in insulin resistance as evidenced by increased glucose/insulin (G/I) ratio (p <0.005) and increased QUICK1 scores (p <0.0005). No significant differences in response to treatment were found between the metformin and OCP groups in outcome variables. Conclusion: Adolescents with PCOS treated with metformin or OCP experienced similar beneficial outcomes including reduction in androgen levels, weight loss, and increased insulin sensitivity. The choice of a treatment agent for long-term use will depend on safety profiles, therapeutic goals and patient adherence.

KW - Adolescent

KW - Metformin

KW - Polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=24944480071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944480071&partnerID=8YFLogxK

M3 - Article

C2 - 16200842

AN - SCOPUS:24944480071

VL - 18

SP - 761

EP - 768

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 8

ER -